Outset Medical (OM)
(Real Time Quote from BATS)
$0.53 USD
-0.04 (-7.54%)
Updated Sep 23, 2024 12:32 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Income Statements
Fiscal Year end for Outset Medical, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 130 | 115 | 103 | 50 | 15 |
Cost Of Goods | 101 | 98 | 95 | 63 | 33 |
Gross Profit | 29 | 18 | 8 | -13 | -18 |
Selling & Adminstrative & Depr. & Amort Expenses | 199 | 179 | 138 | 104 | 53 |
Income After Depreciation & Amortization | -170 | -161 | -131 | -117 | -70 |
Non-Operating Income | 10 | 2 | 1 | -1 | 6 |
Interest Expense | 13 | 4 | 2 | 3 | 4 |
Pretax Income | -172 | -163 | -132 | -121 | -68 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -173 | -163 | -132 | -121 | -68 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -173 | -163 | -132 | -121 | -68 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -170 | -155 | -123 | -114 | -70 |
Depreciation & Amortization (Cash Flow) | -1 | 6 | 7 | 3 | 1 |
Income After Depreciation & Amortization | -170 | -161 | -131 | -117 | -70 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 49.59 | 48.16 | 45.59 | 16.36 | NA |
Diluted EPS Before Non-Recurring Items | -3.48 | -3.38 | -2.89 | -4.85 | NA |
Diluted Net EPS (GAAP) | -3.48 | -3.38 | -2.89 | -4.85 | NA |
Fiscal Year end for Outset Medical, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 27.39 | 28.17 | 30.51 | 30.36 | 36.04 |
Cost Of Goods | 17.61 | 19.95 | 22.80 | 23.21 | 28.34 |
Gross Profit | 9.78 | 8.21 | 7.71 | 7.16 | 7.70 |
SG&A, R&D, and Dept/Amort Expenses | 40.54 | 45.13 | 45.06 | 52.62 | 51.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | -30.76 | -36.92 | -37.35 | -45.46 | -43.49 |
Non-Operating Income | 2.47 | 3.10 | 2.28 | 2.57 | 2.67 |
Interest Expense | 6.01 | 5.97 | 3.42 | 3.21 | 3.10 |
Pretax Income | -34.30 | -39.78 | -38.49 | -46.09 | -43.91 |
Income Taxes | 0.15 | 0.16 | 0.11 | 0.09 | 0.13 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -34.45 | -39.94 | -38.60 | -46.18 | -44.05 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -34.45 | -39.94 | -38.60 | -46.18 | -44.05 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 51.88 | 50.90 | 50.25 | 49.91 | 48.95 |
Diluted EPS Before Non-Recurring Items | -0.66 | -0.73 | -0.77 | -0.93 | -0.90 |
Diluted Net EPS (GAAP) | -0.66 | -0.78 | -0.75 | -0.93 | -0.90 |